Detalhe da pesquisa
1.
Hospital-based health technology assessment in France: A focus on medical devices.
Therapie
; 72(1): 115-123, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28189333
2.
What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France.
Appl Health Econ Health Policy
; 21(5): 799-811, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37253898
3.
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.
Appl Health Econ Health Policy
; 21(6): 905-914, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37751107
4.
Rôle et place de l'évaluation des technologies de santé à l'hôpital : schéma cible appliqué aux dispositifs médicaux.
Therapie
; 72(1): 105-113, 2017 Feb.
Artigo
em Francês
| MEDLINE | ID: mdl-28043648
5.
The new regulatory tools of the 2016 Health Law to fight drug shortages in France.
Health Policy
; 121(5): 471-476, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28366432
6.
The "Temporary Recommendations for Use": A dual-purpose regulatory framework for off-label drug use in France.
Health Policy
; 119(11): 1399-405, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26455642
7.
Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Pharmacoeconomics
; 31(4): 335-43, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23529210
8.
The authors respond to "Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?".
Health Policy
; 120(8): 892-3, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27522451